Computational Chemistry Intern

IBRI is poised to transform life sciences—and for millions of people, even life itself.

The IBRI is seeking motivated undergraduate or graduate students for our Summer Internship Program. Computational Chemistry Research Interns will gain hands‑on experience in a dynamic research environment, contributing to data‑driven projects that support translational science and biomedical innovation.

May 17, 2027 – August 6, 2027

Applications will be accepted through November 30, 2026. For priority consideration, apply by October 15, 2026.

35 hours per week

This internship includes a stipend of $9,650 for the full program, disbursed in bi‑weekly installments on or before the 7th and 22nd of each month

• Construct, run, and analyze molecular dynamics of biological systems and/or quantum chemical simulations of small molecule ligands.
• Assist with modeling, machine learning, or workflow automation projects.
• Create graphs and summaries that make data easier to understand.
• Document code, methods, and results clearly for the team.
• Share progress in meetings and collaborate with experimental scientists.

• Enrolled in (or recently graduated from) an Indiana university undergraduate and/or graduate program OR having graduated from an Indiana High School.
• Degree in a field related computational chemistry research.
• Experience in molecular dynamics or quantum chemical simulations.
• Familiarity with the Linux command line.
• Familiarity with working in high‑performance computing environments is a plus.
• Strong programming skills in scripted languages such as Python.
• Ability to work independently and collaboratively in a research environment.
• Interest in computational biology/chemistry, biomedical data science, or translational research.
• Commitment to the full duration of the internship.
• Excellent organizational and communication skills.

The Indiana Biosciences Research Institute (IBRI) is a first‑in‑class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life.

By connecting early‑stage biotech companies with cutting‑edge life science discoveries —and backed by the mission and resources of industry leaders, investors, and philanthropic partners—IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.

Carefully curating and supporting early‑stage companies with investment, talent, and space, IBRI strategically accelerates drug discovery. Our work benefits from the relatively low cost of living and doing business here, allowing more resources to be directed toward science.

Fueled by the same entrepreneurial creativity as the groundbreaking scientific work we support, IBRI’s labs advance research across the frontiers of diabetes, metabolic disease, Alzheimer’s disease, and rare pediatric diseases. Our ambitious public‑private vision cultivates talent while efficiently bridging the gap between research‑driven inquiry and profit‑driven drug development.

At IBRI, cures are launched on a clear pathway to clinical trials, enabled by the combined resources and experience of our academic and industry partners, without the typical pressure to deliver rapid results for commercialization. IBRI labs pursue breakthroughs that might never happen elsewhere. Breakthroughs are happening here. Our novel financing model ensures that when discoveries are ready for clinical trials, the intellectual property is sold back to industry or spun off, creating a direct stream of revenue.

By every measure, the IBRI model demonstrates a novel approach that delivers rewards. Scientific bench work…